A Chinese biotechnology company has claimed that an experimental anti-aging pill could one day allow humans to live as long as 150 years, though scientists caution that the idea has not been proven in humans.
Shenzhen-based Lonvi Biosciences is developing a capsule made from Procyanidin C1, commonly known as PCC1. The compound is found in grape seed extract and has attracted scientific interest for its potential role in slowing age-related decline.
How the pill is claimed to work
According to the company, the pill targets senescent cells, often described as “zombie cells.” These are old or damaged cells that no longer divide but remain in the body. Over time, they are believed to contribute to chronic inflammation, tissue damage, and various age-related diseases.
Lonvi Biosciences says removing or reducing these cells could help improve overall health in later life and slow the biological aging process. The company has suggested that, combined with other longevity treatments, this approach could make extremely long lifespans possible in the future.
What the science shows so far
The scientific evidence behind PCC1 is currently limited to animal research. A 2021 study published in a peer-reviewed journal reported that PCC1 improved physical health and extended lifespan in mice by selectively targeting senescent cells.
However, medical experts stress that results in mice do not automatically apply to humans. Many treatments that appear promising in animal studies fail to produce the same outcomes in human clinical trials.
Experts urge caution
Researchers say that large-scale, carefully controlled human trials would be required before any claims about significant life extension can be taken seriously. At present, there is no verified clinical evidence showing that PCC1 can dramatically increase human lifespan.
Scientists have also warned that removing senescent cells is a complex process. While these cells can contribute to aging, they may also play certain protective roles in wound healing and tissue repair.
Part of a global longevity race
The interest surrounding the pill reflects China’s broader push into biotechnology and longevity science. Around the world, research groups and companies are increasingly focused on treatments that target the biological mechanisms of aging rather than individual diseases.
For now, experts agree that the pill remains an experimental product rather than a proven life-extension therapy. Whether PCC1 can safely and effectively slow aging in humans will only be known after years of further scientific testing and regulatory review.
Until then, claims of humans living up to 150 years remain speculative and unconfirmed by medical science.
